These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17994116)

  • 1. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy.
    Yao S; McCarthy PL; Dunford LM; Roy DM; Brown K; Paplham P; Syta M; Lamonica D; Smiley S; Battiwalla M; Padmanabhan S; Hahn T
    Bone Marrow Transplant; 2008 Feb; 41(4):393-8. PubMed ID: 17994116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation.
    D'Souza AB; Grigg AP; Szer J; Ebeling PR
    Intern Med J; 2006 Sep; 36(9):600-3. PubMed ID: 16911552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis.
    Cawood TJ; McKenna MJ; Gallagher CG; Smith D; Wen YC; Gibney J; Dodd JD; O'Shea D
    Ir Med J; 2005 Oct; 98(9):270-3. PubMed ID: 16300106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
    Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
    Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
    Ganguly S; Divine CL; Aljitawi OS; Abhyankar S; McGuirk JP; Graves L
    Clin Transplant; 2012; 26(3):447-53. PubMed ID: 22003964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
    Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation.
    Tauchmanovà L; De Simone G; Musella T; Orio F; Ricci P; Nappi C; Lombardi G; Colao A; Rotoli B; Selleri C
    Bone Marrow Transplant; 2006 Jan; 37(1):81-8. PubMed ID: 16247420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis.
    Güler-Yüksel M; Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Groenendael JH; Mallée C; de Bois MH; Breedveld FC; Dijkmans BA; Lems WF
    Ann Rheum Dis; 2009 Mar; 68(3):330-6. PubMed ID: 18375540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate reduces bone loss after allogeneic stem cell transplantation.
    Grigg AP; Shuttleworth P; Reynolds J; Schwarer AP; Szer J; Bradstock K; Hui C; Herrmann R; Ebeling PR
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3835-43. PubMed ID: 16835281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates are effective prophylactic of early bone loss after renal transplantation.
    Nowacka-Cieciura E; Cieciura T; Baczkowska T; Kozińska-Przybył O; Tronina O; Chudziński W; Pacholczyk M; Durlik M
    Transplant Proc; 2006; 38(1):165-7. PubMed ID: 16504693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis.
    Book C; Karlsson M; Akesson K; Jacobsson L
    Scand J Rheumatol; 2008; 37(4):248-54. PubMed ID: 18612924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
    Legroux-Gerot I; Vignau J; Collier F; Cortet B
    Calcif Tissue Int; 2008 Nov; 83(5):315-23. PubMed ID: 18836675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bisphosphonates on bone mineral density after renal transplantation as assessed by bone mineral densitometry.
    Nayak B; Guleria S; Varma M; Tandon N; Aggarwal S; Bhowmick D; Agarwal SK; Mahajan S; Gupta S; Tiwari SC
    Transplant Proc; 2007 Apr; 39(3):750-2. PubMed ID: 17445589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).
    Chapman I; Greville H; Ebeling PR; King SJ; Kotsimbos T; Nugent P; Player R; Topliss DJ; Warner J; Wilson JW
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):838-46. PubMed ID: 18823395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective assessment of bone turnover and clinical bone diseases after allogeneic hematopoietic stem-cell transplantation.
    Petropoulou AD; Porcher R; Herr AL; Devergie A; Brentano TF; Ribaud P; Pinto FO; Rocha V; Peffault de Latour R; Orcel P; Socié G; Robin M
    Transplantation; 2010 Jun; 89(11):1354-61. PubMed ID: 20216480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients.
    Chae YS; Kim JG; Moon JH; Kim SN; Lee SJ; Kim YJ; Sohn SK
    Bone Marrow Transplant; 2009 Jul; 44(1):35-41. PubMed ID: 19139732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation.
    Yao S; Smiley SL; West K; Lamonica D; Battiwalla M; McCarthy PL; Hahn T
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1130-7. PubMed ID: 20188201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.